Myeloma Center

Bibliography

Found 8 results
Author Title Type [ Year(Asc)]
Filters: Keyword is Male and Author is Coleman, Morton  [Clear All Filters]
2017
Mark TM, Guarneri D, Forsberg P, Rossi A, Pearse R, Perry A, Pekle K, Tegnestam L, Greenberg J, Shore T et al..  2017.  A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.. Biol Blood Marrow Transplant. 23(6):930-937.
2014
Mark TM, Bowman IA, Rossi AC, Shah M, Rodriguez M, Quinn R, Pearse RN, Zafar F, Pekle K, Jayabalan D et al..  2014.  Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.. Leuk Lymphoma. 55(12):2842-9.
2013
Mark TM, Reid W, Niesvizky R, Gergis U, Pearse R, Mayer S, Greenberg J, Coleman M, van Besien K, Shore T.  2013.  A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.. Biol Blood Marrow Transplant. 19(5):831-7.
2010
Gay F, S Rajkumar V, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ et al..  2010.  Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.. Am J Hematol. 85(9):664-9.
2008
Mark T, Jayabalan D, Coleman M, Pearse RN, Y Wang L, Lent R, Christos PJ, Lee JW, Agrawal YP, Matthew S et al..  2008.  Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.. Br J Haematol. 143(5):654-60.
Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, Jalbrzikowski J, Pearse RN, Zafar F, Pekle K et al..  2008.  BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.. Blood. 111(3):1101-9.
Mark T, Stern J, Furst JR, Jayabalan D, Zafar F, Larow A, Pearse RN, Harpel J, Shore T, Schuster MW et al..  2008.  Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.. Biol Blood Marrow Transplant. 14(7):795-8.
2007
Niesvizky R, Martínez-Baños D, Jalbrzikowski J, Christos P, Furst J, De Sancho M, Mark T, Pearse R, Mazumdar M, Zafar F et al..  2007.  Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma.. Leuk Lymphoma. 48(12):2330-7.